| Literature DB >> 23319889 |
Abdullah Demirtas1, Yunus Emre Yildirim, Mustafa Sofikerim, Esma Gunduz Kaya, Emre Can Akinsal, Sevket Tolga Tombul, Oguz Ekmekcioglu, Ibrahim Gulmez.
Abstract
This study aimed at determining the choice and administration duration of ideal antibiotic prophylaxis before percutaneous nephrolithotomy (PNL) operation, a treatment modality for nephrolithiasis. The study included 90 patients who had no internal problem, yet had a negative urine culture and underwent a PNL operation. We compared infection rates between ciprofloxacin and ceftriaxone groups and their subgroups. The results showed no statistical difference between ciprofloxacin and ceftriaxone groups in terms of systemic inflammatory response syndrome (SIRS) (CIP(P) = 0.306, CTX P = 0.334. As a result of this study no statistical difference was observed between ciprofloxacin and ceftriaxone in terms of SIRS. It seems, however, reasonable to choose ceftriaxone, considering antibiotic sensitivity of microorganisms and detection of three cases accepted as urosepsis in the ciprofloxacin group. As there is no difference between short, and long-term prophylactic use of these antibiotics, preference of short-term prophylaxis for patients with no risk of infection will be important to avoid inappropriate antibiotic usage.Entities:
Mesh:
Substances:
Year: 2012 PMID: 23319889 PMCID: PMC3539373 DOI: 10.1100/2012/916381
Source DB: PubMed Journal: ScientificWorldJournal ISSN: 1537-744X
Number of SIRS cases among antibiotic groups.
| Ciprofloxacin (CIPRO) | Ceftriaxone (CTX) | |||||||
|---|---|---|---|---|---|---|---|---|
| 1st Group | 2nd Group | 3rd Group | Total ( | 1st Group | 2nd Group | 3rd Group | Total ( | |
| SIRS (+) | 1 (2.2%) | 2 (4.4%) | 4 (8.8%) | 7 (15.5%) | 2 (4.4%) | — | 2 (4.4%) | 4 (8.8%) |
| SIRS (−) | 14 (31.1%) | 13 (28.8%) | 11 (24.4%) | 38 (84.4%) | 13 (28.8%) | 15 (33.3%) | 13 (28.8%) | 41 (91.1%) |
|
| ||||||||
| Total ( | 15 (33.3%) | 15 (33.3%) | 15 (33.3%) | 45 (100%) | 15 (33.3%) | 15 (33.3%) | 15 (33.3%) | 45 (100%) |
*No significant difference between ciprofloxacin and ceftriaxone in terms of SIRS (P = 0.52).
**No statistically significant difference between subgroups of both antibiotics in terms of SIRS positivity (CIP P = 0.306, CTX P = 0.334).
*** No significant difference between short- and long-term groups of both ciprofloxacin and ceftriaxone in terms of SIRS (CIP P = 0.19, CTX P = 0.59).
****Chi-Square test.
Comparison of the predictive factors affecting SIRS positivity among antibiotic groups.
| CIPRO | CTX | |||||
|---|---|---|---|---|---|---|
| SIRS | SIRS | |||||
| (+) | (−) |
| (+) | (−) |
| |
| Stone burden (cm2) | 5.2 | 4.2 | 0.032 | 4.1 | 5.9 | 0.873 |
| Operation duration (min) | 124 | 72 | 0.025 | 112 | 89 | 0.115 |
| Amount of NaCl (liter) | 12 | 9.4 | 0.220 | 15 | 11 | 0.297 |
| Duration of nephrostomy (day) | 5.8 | 3.1 | 0.003 | 4.5 | 2.7 | 0.009 |
| Multiple access | 71.4% | 26.3% | 0.032 | 25% | 31.7% | 1.000 |
| Presence of obstruction | 42.9% | 44.7% | 1.000 | 25% | 26.8% | 1.000 |
| Lithotripter use | 100% | 71.7% | 0.168 | 50% | 82.9% | 0.173 |
*Mann-Whitney U test.
Effect of culture positivity on SIRS between CIPRO and CTX groups.
| CIPRO | CTX | |||||
|---|---|---|---|---|---|---|
| SIRS | SIRS | |||||
| (+) | (−) |
| (+) | (−) |
| |
| (+) Stone culture (%) | 14.3% | 26.3% | 0.663 | 25% | 39% | 1.000 |
| (+) Renal pelvis urine culture (%) | 14.3% | 2.6% | 0.290 | 0 | 2.4% | 1.000 |
| (+) Postop. urine culture (%) | 42.9% | 13.9% | 0.094 | 0 | 7.3% | 1.000 |
*No statistically significant difference was observed in positive cultures between ceftriaxone and cetrifiaxone in terms of SIRS positivity. (P > 0.05).
**Chi-Square test.
Distribution of isolated microorganisms between antibiotic groups.
| Pelvic system culture | Stone culture | Postop. urine culture | ||||
|---|---|---|---|---|---|---|
| CIPRO | CTX | CIPRO | CTX | CIPRO | CTX | |
|
| 2 | — | 1 | 5 | 3 | 1 |
| Coagulase (−) | — | — | 8 | 10 | 3 | 1 |
|
| — | — | — | 2 | — | — |
|
| — | — | — | — | 2 | 1 |
|
| — | — | — | — | 1 | — |
|
| — | 1 | 1 | — | — | — |
| Proteus | — | — | 1 | — | — | — |
|
| — | — | — | — | 1 | — |
| Others | — | — | — | — | 2 | — |